Extended Data Fig. 9: Drugs differentially activate the SLFN11 cell death response.
From: RPA exhaustion activates SLFN11 to eliminate cells with heightened replication stress
(a) A dose response curve measuring cell viability in the presence of indicated concentrations of ST1926, a DNA polymerase alpha inhibitor. (b) A dose response curve measuring cell viability in the presence of indicated concentrations of olaparib, a PARP inhibitor. (c) A dose response curve measuring cell viability in the presence of indicated concentrations of camptothecin (CPT), a topoisomerase I inhibitor. (d) A dose response curve measuring cell viability in the presence of indicated concentrations of benzo(a)pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE). (e) A dose response curve measuring cell viability in the presence of indicated concentrations of methyl methanesulfonate (MMS). (f) A dose response curve measuring cell viability in the presence of indicated concentrations cisplatin. (g) A dose response curve measuring cell viability in the presence of indicated concentrations of mitomycin C (MMC). (h) A dose response curve measuring cell viability in the presence of indicated concentrations of AZD6738, an ATR inhibitor. (i) A dose response curve measuring cell viability in the presence of indicated concentrations of hydroxyurea (HU), an inhibitor of ribonucleotide reductase. (j) A dose response curve measuring cell viability in the presence of indicated concentrations of bleomycin. (k) A dose response curve measuring cell viability in the presence of indicated concentrations of KU-5593, an ATM inhibitor. All experiments were performed in N = 3 biological replicates. Data are represented as means ± SD. (l) A dose response curve measuring cell viability in the presence of indicated concentrations of B02, a RAD51 inhibitor. Source numerical data are available in the source data.
